New treatments for Ewing sarcoma using SIRT5 inhibitors
SIRT5 inhibitors and degraders as novel treatments for Ewing sarcoma
This study is exploring new ways to treat Ewing sarcoma, a tough cancer that mostly affects kids and young adults, by looking at how blocking a specific protein called SIRT5 can help kill cancer cells and improve treatment results.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Miami School of Medicine NIH-funded |
| Lab location | 1 site (Coral Gables, United States) |
| Project ID | NIH-11005706 on NIH RePORTER |
What this research studies
This research investigates the potential of SIRT5 inhibitors and degraders as novel treatments for Ewing sarcoma, a type of aggressive cancer primarily affecting children and young adults. The approach focuses on targeting the SIRT5 protein, which plays a crucial role in cancer cell survival. By depleting SIRT5, the researchers aim to induce apoptosis, or programmed cell death, specifically in Ewing sarcoma cells, potentially leading to improved treatment outcomes. The study will involve laboratory experiments to assess the effectiveness of these inhibitors in preclinical models of Ewing sarcoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are children and young adults diagnosed with Ewing sarcoma, especially those with advanced stages of the disease.
Not a fit: Patients with other types of cancers or those who do not have Ewing sarcoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option for patients with Ewing sarcoma, particularly those with metastatic or recurrent disease.
How similar studies have performed: While the specific approach targeting SIRT5 in Ewing sarcoma is novel, similar strategies targeting other cancer-related proteins have shown promise in previous studies.
Where this research is happening
Coral Gables, United States
- University of Miami School of Medicine — Coral Gables, United States (Active)
Researchers
- Principal investigator: Lombard, David Benner — University of Miami School of Medicine
- Study coordinator: Lombard, David Benner
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.